Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001999371-25-011273 0001131399 XXXXXXXX LIVE 1 Common Shares, par value (euro) 0.12 per share 12/03/2025 true 0001809122 N2451R105 CureVac N.V. Friedrich-Miescher-Strasse 15 Tubingen 2M 72076 Victoria A. Whyte 44 020 8047 5000 79 New Oxford Street London X0 WC1A 1DG 0001131399 N GSK plc OO N X0 0.00 0.00 0.00 0.00 0.00 N 0.00 HC (1) Common Shares previously reported were held directly by Glaxo Group Limited ("GGL"), an indirect wholly-owned subsidiary of GSK plc. Common Shares, par value (euro) 0.12 per share CureVac N.V. Friedrich-Miescher-Strasse 15 Tubingen 2M 72076 This Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the statement on Schedule 13D originally filed by GSK plc ("GSK") with the Securities and Exchange Commission on August 13, 2025 (the "Schedule 13D") with respect to the common shares, (euro) 0.12 par value per share (the "Common Shares"), of CureVac N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (the "Issuer"), whose principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 Tubingen, Germany. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D. This Amendment No. 1 is the final amendment to the Schedule 13D and constitutes an "exit filing" for GSK. Item 2(c) of the Schedule 13D is hereby amended by deleting Schedule A in its entirety and replacing it with Schedule A attached hereto to reflect updates to the titles and honorifics of certain directors and executive officers of GSK. Item 4 of the Schedule 13D is hereby amended by adding the following: Pursuant to the terms of the Tender and Support Agreement, GGL tendered all Common Shares held by it in the Exchange Offer. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Common Shares held by GGL were accepted for exchange on December 3, 2025. As a result, GSK, through its wholly-owned indirect subsidiary GGL, no longer beneficially owns, or otherwise holds, any securities of the Issuer. Item 5(a) of the Schedule 13D is hereby amended and restated as set forth below: The responses of GSK to Rows (7) through (13) of the cover pages of this Amendment No. 1 are hereby incorporated by reference in this Item 5(a). Item 5(b) of the Schedule 13D is hereby amended and restated as set forth below: Except as disclosed in this Amendment No.1, neither GSK nor, to the best of its knowledge, any of the persons listed in Schedule A to the Schedule 13D, (i) beneficially owned, or had the right to acquire, any Common Shares, or (ii) had the power to vote or to direct the vote, or to dispose or direct the disposition, of any of the Common Shares. Item 5(c) of the Schedule 13D is hereby amended and restated as set forth below: Except as disclosed in Item 4, neither GSK nor, to the best of its knowledge, any of the persons listed in Schedule A of the Schedule 13D, has effected any transaction in the Common Shares during the past sixty (60) days. December 3, 2025. GSK plc /s/ Victoria A. Whyte Victoria A. Whyte, Authorized Signatory 12/05/2025